ImmunityBio Inc - Company Profile
Powered by 
All the sales intelligence you need on ImmunityBio Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how ImmunityBio Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with ImmunityBio Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ImmunityBio Inc (ImmunityBio), a subsidiary of NantWorks LLC, is a clinical-stage biotechnology company that develops innovative treatments for advanced cancers and infectious diseases. The company pipeline products including ANKTIVA + M-ceNK for advanced solid tumors; ANKTIVA + BCG and Recombinant BCG (rBCG) treats bladder cancer; ANKTIVA + Tri-Ad5 vaccines targets colorectal cancer and lynch syndrome; ANKTIVA + bevacizumab + PD-L1 t-haNK for the treatment of glioblastoma; ANKTIVA which treats HIV; and ANKTIVA + Ad5 HPV targets human papillomavirus, among others. It operates in Italy, South Korea and the US. ImmunityBio is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
3530 John Hopkins Court, San Diego, California, 92121
Website
immunitybio.com
Telephone
1 844 6965235
No of Employees
691
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IBRX (NASD)
Revenue (2024)
$113.3M
668.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
15%
(2024 vs 2023)
Market Cap*
$8.1B
Net Profit Margin (2024)
XYZ
88.9%
(2024 vs 2023)
* As of and is in US$
ImmunityBio Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | ImmunityBio |
| Bladder Cancer: | ImmunityBio Care |
| Anktiva + BCG | ANKTIVA |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In May, the company signed an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory to offer ImmunityBio exclusive U.S. rights to develop, import, and commercialize intravesical Tokyo-172 BCG. |
| 2026 | Regulatory Approval | In March, the company received approval from the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China for ANKTIVA. |
| 2026 | Contracts/Agreements | In February, the company partnered with Biopharma and Cigalah to introduce ANKTIVA (nogapendekin alfa inbakicept) in Saudi Arabia and across the MENA region. |
Competitor Comparison
| Key Parameters | ImmunityBio Inc | Merck & Co Inc | AbbVie Inc | Precigen Inc | Ferring International Center SA |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Switzerland |
| City | San Diego | Rahway | North Chicago | Germantown | Saint-Prex |
| State/Province | California | New Jersey | Illinois | Maryland | Waadt |
| No. of Employees | 691 | 75,000 | 57,000 | 160 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Patrick Soon-Shiong, M.D. | Chief Medical Officer; Chairman; Chief Scientific Officer | Executive Board | 2014 | 72 |
| Richard Adcock | Chief Executive Officer; Director; President | Executive Board | 2021 | 56 |
| Barry J. Simon, M.D. | Chief Corporate Affairs Officer; Director | Executive Board | 2017 | 60 |
| David C. Sachs | Chief Financial Officer | Senior Management | 2021 | 47 |
| Leonard S. Sender, M.D. | Chief Operating Officer | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer